Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fujifilm to Enter into Capital Partnership with J-TEC
September 13, 2010
- Sutent Does Not Extend OS in NSCLC in PIII: Pfizer
September 13, 2010
- New PFSB Director General to Place Top Priority on Prevention of Drug-Induced Health Damage
September 13, 2010
- Lilly Applies for Gemzar for Ovarian Cancer Based on Data from Public Domain
September 13, 2010
- Eisai Begins PI Study for BAN2401 in the US
September 13, 2010
- Korosho Demands ¥28,795.4 Bil. General Account Budget for FY2011
September 13, 2010
- Humira Applied for JIA in Japan: Abbott, Eisai
September 13, 2010
- No Significant Differences in ADRs between Avandia, Actos: HealthCore
September 13, 2010
- Korosho Demands Budgets to Develop Buried Seeds of Drugs
September 13, 2010
- FDA Extends Review of Eribulin NDA: Eisai
September 13, 2010
- Expand Range of Indications for Palivizumab: Dr Watabe
September 13, 2010
- Working Groups Created to Assess 8 Vaccines
September 13, 2010
- SRSM Created to Promote Regulatory Sciences
September 13, 2010
- Appeal Trial Begins on Online Sale of Classes 1, 2 OTC Drugs
September 13, 2010
- Addition of New Indications Unlikely to Make Any Drugs Eligible for Re-Pricing
September 13, 2010
- Sawai, Medisa to Recall Generics for Bromocriptine
September 13, 2010
- Orencia to Boost BMKK's Sales
September 13, 2010
- Nippon Kayaku Applies for Hycamtin Based on Data from Public Domain
September 13, 2010
- Nippon Chemiphar to Terminate Alliance with Nihon Chouzai
September 13, 2010
- Takeda Licenses Contrave from Orexigen
September 13, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…